8:00 a.m.

Registration and Continental Breakfast

9:00 a.m.

Welcome and Opening Remarks, Heidi Leenay, Vice President, OptumHealth Education

9:30 a.m.

KEYNOTE ADDRESS—Live-Donor Liver Transplant: Changing the Paradigm, Abhinav Humar, MD, UPMC; Rina Kader, Living Liver Donor; and Wayne Livingston, Liver Transplant Recipient

Live-donor liver transplantation (LDLT) has been perfected for children and adults with serious liver disease. Both a donor and a recipient of a live-donor liver transplant will highlight the benefits and potential complications of this life-saving surgery. The optimal time for a LDLT to maximize outcomes will also be discussed.

Learning objectives:

1. Highlight the advantages and disadvantages of LDLT for individuals with liver failure.
2. State strategies that may be utilized to increase the availability of LDLT.
3. Discuss the risks and complications associated with living donation.
4. Identify the optimal time for LDLT to maximize outcomes.

10:30 a.m.

Break

10:45 a.m.

Update in the Utilization of Blood/Marrow Transplant (BMT) and Emerging Diagnoses on the Horizon, Krishna Komanduri, MD, Sylvester Comprehensive Cancer Center, University of Miami Health System

The number of BMTs performed every year in the U.S. has markedly increased over the last two decades and doubled between 2000 and 2015. Factors that contribute to the rising incidence of BMTs include expansion of populations in which BMT is most commonly used, increases in unrelated-donor registries and cord blood inventories, improved outcomes in unrelated-donor transplants, and higher rates of BMT with less-intense conditioning regimens in older patients. This session will discuss contributing factors to the increase in BMT utilization and emerging indications.

Learning objectives:

1. Summarize contributing factors and issues related to increasing rates of BMT utilization.
2. Outline current and emerging indications for BMT.

11:30 a.m.

The Increase in Suicide Across the U.S., Jill Harkavy-Friedman, PhD, American Society for Suicide Prevention

Suicide is the 10th-leading cause of death in the United States. It is the second-leading cause of death among people ages 10–34 and the fourth-leading cause among people ages 35–54. Suicide is a tragedy for families and communities across the country. This presentation will discuss factors that contribute to the increase in suicide across all age groups and identify the role HCPs can play in efforts to reverse this troubling increase in incidence.

Learning objectives:

1. Identify factors that contribute to suicide among different age groups.
2. State how adolescent depression and suicidal feelings may be recognized, diagnosed and appropriately managed.
3. State the role health care professionals can play in efforts to help save lives and reverse this troubling rise in suicide.

12:15 p.m.

Luncheon Presentation—The Future of Health Care, Richard Migliori, MD, Executive Vice President and Chief Medical Officer, UnitedHealth Group; and Wyatt W. Decker, MD, MBA, Chief Executive Officer, OptumHealth (nonaccredited/optional; lunch provided) 

1:30 p.m.

Exhibit Hall Grand Opening Dessert Reception

2:30 p.m.

End-of-Life Care in America: Ethics Is Quality, Quality Is Ethics, Nneka O. Sederstrom, PhD, MPH, MA, FCCP, FCCM, Children's Minnesota

Taking care of patients and their families as they face end-of-life (EOL) care decisions is an important and difficult role that health care professionals (HCPs) face. It is often challenging and can reveal conflicting values and goals among the providers, patients, and their families. This presentation will address the importance of recognizing goals of EOL care and barriers that prevent them from being met. It will also discuss how improving EOL care can both ease the challenge of difficult decisions for patients and their families and improve quality for the entire health care system.

Learning objectives:

1. Recognize the main goals that are important to individuals at EOL.
2. State barriers that prevent the majority of EOL goals from being met.
3. Identify strategies in which the EOL experience can be improved to provide high quality, reliable and ethically sound care.
4. Explain how EOL care is related to health care costs.

3:30 p.m.
New topic

The Case for Community-based, High-Risk Women’s Cancer Programs, Dax Kurbegov, MD, Sarah Cannon

Genetic risk assessment can play a critical role in helping to reduce the incidence of hereditary breast and ovarian cancer by identifying women with elevated risk. Great challenges exist in the successful implementation of a high-risk women’s cancer program because primary care providers, breast- and ovarian-care specialists, administrators, and support staff must work together in a multidisciplinary manner to achieve the common goal. This presentation will highlight key considerations in implementing a multidisciplinary program for women at increased risk for cancer and genetic mutation carriage. The role of genetic risk assessment and the importance of distinguishing the risk of carrying a hereditary cancer gene versus specific risk of developing breast and ovarian cancer will also be discussed.

Learning objectives:

1. Provide an update on the current state of genetic risk assessment for women’s cancer risk.
2. Examine the importance of distinguishing risk of carrying a hereditary cancer gene versus specific risk of developing breast/ovarian cancer.
3. Describe key considerations in implementing multidisciplinary high-risk women’s programs.

4:15–5:00 p.m.

Transplant Trends: Current Data and Statistics, Sommer Gentry, PhD, Johns Hopkins University School of Medicine

The need for organ donation is immense. This presentation will discuss the use of national data to identify strategies to drive improvement in donation and address inequities in transplant.

Learning objectives:

1. Explain how national data is used to develop strategies to drive improvement and address inequities in transplant.
2. Explore utilization, innovation, and donation trends in transplant, including strategies to increase utilization and improve access to organ transplant.

5:00–6:30 p.m.

Networking Reception—Exhibits Open
Support provided by UPMC.

7:15–8:15 a.m.

12th Annual Wellness Walk—A two- or three-mile walk/run along a uniquely scenic pathway through the Minneapolis park system. Route Map

8:00 a.m.

Registration and Continental Breakfast

9:00 a.m.

Welcome and Opening Remarks, Heidi Leenay, Vice President, OptumHealth Education

9:15 a.m.

The CAR T-cell Therapy Tsunami: Emerging Therapies and Barriers to Access, C. Fred LeMaistre, MD, Sarah Cannon

Chimeric antigen receptor (CAR) T-cell therapy has the potential to revolutionize cancer treatment. This therapy is expected to expand quickly with the number of clinical trials increasing by 113 percent over the last year! This session will explore the complexities of CAR T-cell therapy, explain how it works, and discuss the future applications we may expect to see in this field.

Learning objectives:

1. Explain how CAR T-cell therapy works.
2. Identify the currently available and emerging CAR T-cell therapies for relapsed or refractory (R/R) malignancies.
3. Describe logistical and infrastructure complexities for CAR T-cell therapy.
4. Explore the barriers to access for CAR T-cell therapy.
5. Discuss potential future applications of CAR T-cell therapy.

10:15 a.m.

Value in Cancer Care: Finding the Path to Progress, Yousuf Zafar, MD, MHS, FASCO, Duke Cancer Institute

The cost of cancer care in the U.S. has increased dramatically over the last three decades. Among factors contributing to this huge increase are rising cancer prevalence, due in part to our aging population, and the rapidly increasing cost of pharmaceuticals and other interventions. Mounting physician fees and cost-sharing on the part of the insurance industry have also made a significant contribution. Clearly as our health care system continues to shift from a focus on volume to one centered on value, innovative approaches to enhance value will be needed. Unfortunately, the path ahead is far from clear, in part because of the complexity of the disease itself.

Learning objectives:

1. Identify factors contributing to the continuing increase in the cost of cancer care over the last three decades.
2. Explore ways that quality and value can be best measured in cancer care.
3. Describe innovative strategies that may be utilized to help increase value of cancer care at all levels of the health care system.

11:00 a.m.

Break—Exhibits Open

12:00 p.m.

Lunch (provided)—Exhibits Open

12:30 p.m.

Optimizing Care for Individuals with Type 2 Diabetes and Cardiovascular Disease: a Multidisciplinary Approach, Christopher B. Granger, MD, Duke University School of Medicine

The public health impact of T2D and cardiovascular disease (CVD) in the U.S. is immense — compared to people without diabetes, patients with diabetes are two–four times more likely to develop CVD. Several medications for T2D have been found to reduce cardiovascular events and mortality in patients with T2D, however treatments are not consistently used and preventable death and disability are occurring. This presentation will identify ways in which, through a multidisciplinary team approach, specific interventions at cardiology clinics may be applied to achieve best practices in improving patient care.

Learning objectives:

1. State the importance of a multidisciplinary approach to optimally manage individuals with T2D and CVD.
2. Identify interventions that may be employed to achieve best practices to improve patient health for individuals with T2D and CVD.
3. Summarize current guideline recommendations for reducing cardiovascular risk in patients with T2D.

1:30 p.m.

Hepatitis C Virus (HCV)-Positive Donors for Uninfected Recipients: Are High-Risk Donors a Potential Cost-Effective Approach to Save Lives? John P. Roberts, MD, University of California San Francisco

Innovations in liver transplantation have been developed to address the ongoing shortage of donor organs and to optimize outcomes. Livers from donors who are infected with HCV are commonly transplanted into recipients who are also HCV-positive. But the number of HCV-positive recipients is decreasing, while the donor pool of HCV-positive livers is expanding due to the opioid epidemic. Transplanting HCV-positive livers into HCV-negative recipients may be a novel strategy for addressing the liver donor organ shortage and may be cost effective as well.

Emerging data suggest that short-term outcomes in HCV-negative recipients of HCV-positive livers are similar to those of recipients of HCV-negative livers.

Learning objectives:

1. Describe the risks and benefits of transplanting HCV-positive donor livers in HCV-negative recipients, including cost of treatment and outcomes.
2. Identify the increase in HCV-positive donors as related to the opioid epidemic.
3. Explain why those awaiting liver transplant are more likely to accept an organ that is identified as “increased-risk” than those awaiting other organs.

2:15 p.m.

Break—Exhibits Open

3:00 p.m.

Where Have All the Pancreata Gone? A Crisis in Modern Day Transplantation, Dixon B. Kaufman, MD, PhD, FACS, UW Health

Pancreas and islet cell transplantation is recommended for patients with type 1 diabetes and select patients with type 2 diabetes (T2D) to treat or prevent complications from diabetes. While more than 90 percent of patients with diabetes have T2D, pancreas transplantation is underused in this population. Furthermore, the number of pancreas transplants in the United States has been declining since 2004. This presentation will identify the indications for pancreas transplant for T2D and factors contributing to the decreased use of pancreas transplant, as well as compare the benefits of pancreas transplant versus insulin pumps for this population.

Learning objectives:

1. State the indications or evidence supporting patient selection for pancreas transplantation in patients with T2D.
2. Discuss the risks, benefits and strategies for patient selection regarding pancreas transplantation versus insulin pumps in the treatment of diabetes.
3. Identify factors contributing to the significant decrease in pancreas transplant and strategies that may be applied to change this pattern.

4:00-5:00 p.m.

Optimizing Care for Children with Medical Complexity: The Team-Based Approach, Amie Jones, MD, Mayo Clinic

Children with special health care needs (CSHCN) have, or are at increased risk for chronic physical, developmental, and behavioral or emotional conditions and require an array of HCPs to manage their care. An effective multidisciplinary team approach designed to work on the common goal of improved patient-centered care is essential to addressing the fragmented and often inefficient care that these children frequently encounter and building systems that work for their complex health care needs. This presentation will address the impact of interprofessional collaboration in creating a multidisciplinary team approach for CSHCN.

Learning objectives:

1. State the key components of establishing an effective multidisciplinary team to optimally manage CSHCN.
2. Explain the importance of communication as a core component of an interprofessional team approach to managing CSHCN.
3. Compare and contrast effective communication methodologies among members of the interprofessional health care team and identify practical solutions for effective collaboration for CSHCN.

5:00–6:30 p.m.

Optum Provider Network Reception (Ticketed event; by invitation only.)

5:00–7:00 p.m.

Optum Client Reception (invitation only)

7:45–8:45 a.m.

Optum Client Breakfast, Roger Shedlin, MD, JD, Chief Executive Officer, and Jon Friedman, MD, FAST, Chief Medical Officer, Optum Medical Benefit Management (Ticketed, nonaccredited event; by invitation only.)

8:00 a.m.

Continental Breakfast

9:00 a.m.

Cancer Survivorship: A Personalized Precision Approach, Deborah K. Mayer, PhD, RN, AOCN, FAAN, University of North Carolina

Numerous genetic and environmental factors influence cancer prognosis and outcomes. The interaction between genetic and environmental risk factors for cancer is complex, but understanding how they influence cancer risk and prognosis can lead to personalized treatment and a more precise prediction of outcomes. Risk prediction models for certain types of cancers based on environmental and genetic risk factors are currently being developed. Furthermore, with continually rising BMT rates and improving outcomes post-BMT, survivorship issues post-BMT are becoming increasingly important.

Learning objectives:

1. Explore genetic factors that may increase or decrease cancer risk.
2. Describe prediction tools for cancer outcomes that incorporate genetic and environmental risk factors.
3. Explain how environmental exposure affects cancer survivorship.
4. State the future of individualized cancer therapies and a personalized precision approach.

10:00 a.m.

Break

10:15 a.m.

Infectious Disease Challenges in Solid Organ Transplantation (SOT), Jay A. Fishman, MD, Massachusetts General Hospital

The potential etiologies of infection are diverse and can often progress rapidly in SOT patients. Many challenges exist in the prevention, diagnosis, clinical consequences, and management of infectious disease in transplant recipients with emerging issues, including donor-derived infection, the impact of pandemic influenza in the SOT recipient, and drug-resistant infections. This presentation will identify atypical presentations of infections in SOT and explore future directions in diagnostics and therapeutics in this field.

Learning objectives:

1. Identify atypical presentations of infection in transplantation.
2. List infectious risks associated with immunosuppression.
3. Recognize donor-derived infections, including HIV.
4. State future directions in diagnostics and therapeutics of transplant infectious disease.

11:15 a.m.

Advances in Abdominal Transplant in the Last Quarter Century, Charles M. Miller, MD, Cleveland Clinic

Throughout the past quarter century, we have witnessed radical treatment advances and major developments in organ transplantation. This presentation will highlight the past 25 years of momentous advances and innovations in abdominal transplantation.

1. Identify developments that have been made in abdominal transplantation during the last quarter century.
2. Explore whether this progression in abdominal transplant can be sustained and accelerated.
3. Explain how government policies have influenced past events or could influence further developments in transplantation.

12:00 p.m.

Adjourn